New treatments for common cardiovascular risk factor near the market, with billions at stake Unlike cholesterol, there is no approved therapy to lower levels of Lp(a)

https://www.statnews.com/2026/08/26/lp-a-drugs-novartis-amgen-lilly-potential-heart-disease-blockbuster/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-_j4oc0kn055CeJne1-XYT4EKk-0YYxqdval9J2yCLQxPPgNsglbo2adBj-wS3Z_b_pG-Cbth2Areh__uFg4NniwsTHqA&_hsmi=435329184&utm_content=435329184&utm_source=hs_email By Andrew JosephAug. 26, 2026 Europe Correspondent